Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study

• Asıl Yazarlar: Benjamin Rossi (Yazar), Lee S. Nguyen (Yazar), Philippe Zimmermann (Yazar), Faiza Boucenna (Yazar), Louis Dubret (Yazar), Louise Baucher (Yazar), Helene Guillot (Yazar), Marie-Anne Bouldouyre (Yazar), Yves Allenbach (Yazar), Joe-Elie Salem (Yazar), Paul Barsoum (Yazar), Arezki Oufella (Yazar), Helene Gros (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2020-10-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted for severe COVID-19 pneumonia (SpO₂ ≤ 96% despite O₂-support ≥ 6 L/min) w...